ObjectiveTo analyze the disease burden and evolving trends for gastric cancer in China and worldwide from 1990 to 2021. MethodsBased on the 2021 Global Burden of Disease (GBD) database, we analyzed the burden of gastric cancer using indicators such as incidence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lost due to disability (YLDs). Joinpoint regression analysis was used to calculate the average annual percentage change (AAPC) of these indicators to show trends over time. ResultsIn 2021, the standardized incidence rate of gastric cancer was 14.33 (per 100 000) worldwide and 29.05 (per 100 000) in China, with corresponding standardized mortality rates of 11.20 (per 100 000) and 21.51 (per 100 000). The standardized incidence rate of gastric cancer in China trended downward during 1990–2021 (AAPC=–1.61%, P<0.05), but was lower than the global decline (AAPC=–1.77%, P<0.05). During 1990-2021 in China, the rates of standardized DALYs (AAPC=–2.76%, P<0.05), standardized YLLs (AAPC=–2.78%, P<0.05) and standardized YLDs (AAPC= –1.25%, P<0.05) all showed a significant decrease. The global rates of standardized DALYs (AAPC=–2.42%, P<0.05), standardized YLLs (AAPC=–2.44%, P<0.05) and standardized YLDs (AAPC=–1.56%, P<0.05) all showed a significant decrease. These AAPC values above indicated a general attenuation in the gastric cancer burden across all age groups, both in China and worldwide. ConclusionsDespite these signs of a decline in disease burden indicators for gastric cancer in China and worldwide, the number of cases and deaths in gastric cancer remains substantial coupled with the heavy burden on the healthcare system. Therefore, increased efforts in early detection and prevention strategies are of utmost importance to further reduce the impact of this malignant disease.
Objective To summary the incidence rate and trends of malignant tumor in China. MethodsBy compiling and analyzing the Chinese Cancer Registry Annual Report from 2008 to 2021, we summarized the regional and population distribution characteristics of overall and high-incidence rate malignant tumors in China and analyzed influencing factors. ResultsFrom 2005 to 2018, the overall crude incidence of malignant tumors in China showed a continuous upward trend. The incidence rate in the eastern region (incidence rate was 353.26/100 000 in 2018; hereafter the same) was significantly higher than those in the central (269.47/100 000) and western regions (253.71/100 000), while the incidence rates in the central and western regions were closer. 2005–2018, the incidence rate of males was higher than that of females, and the population aged 80 years old or older (2 741.02/100 000) had the highest incidence rate of malignant tumors, and the incidence rate of people aged 0–14 years (41.38/100 000) was the lowest. From 2005–2018 (except for 2009), lung cancer (65.05/100 000), gastric cancer (27.03/100 000), liver cancer (27.42/100 000), colorectal cancer (30.51/100 000), and breast cancer (43.02/100 000) were the top 5 highest incidence rates of China’s malignant tumors, of which lung cancer ranked the first in different regions, and the ranking of other cancers varied in different regions. The top 5 tumors in males incidence rate from 2005 to 2018 were lung cancer (83.45/100 000), gastric cancer (37.12/100 000), liver cancer (40.02/100 000), colorectal cancer (35.32/100 000) and esophageal cancer (26.30/100,000); the top 5 tumors in females incidence rate had changed a lot in different years, breast cancer, lung cancer, colorectal cancer, gastric cancer, liver cancer, thyroid cancer and cervical cancer had all been in the top 5, for example, in 2018, the top 5 malignant tumors in females were lung cancer (46.10/100 000), breast cancer (43.02/100 000), colorectal cancer (25.56/100 000), thyroid cancer (24.60/100 000) and cervical cancer (18.10/100 000). ConclusionsThe crude incidence rate of malignant tumors in China continues to rise, with the cancer spectrum showing new characteristics that combine high-incidence rate cancers in developed countries (e.g., breast cancer, colorectal cancer) with common cancers in developing countries (e.g., gastric cancer, liver cancer). The situation of malignant tumor prevention and control remains challenging.